Table 2.

The mean changes in efficacy variables with solifenacin and tolterodine from baseline to end-point

	Solifenacin succinate
	5 mg qd	l0 mg qd	Tolterodine 2 mg bid
Mean daily micturition frequency
Baseline	11.26 ± 2.78	11.19 ± 2.82	11.44 ± 2.81
Visit 3	9.60 ± 2.46	9.21 ± 2.46	9.88 ± 2.48
Visit 4	9.37 ± 2.87	8.83 ± 2.63	9.76 ± 2.63
Visit 5	9.01 ± 2.70	8.59 ± 2.70	9.23 ± 2.64
End-point	9.08 ± 2.58	8.71 ± 2.73	9.30 ± 2.61
End-point baseline (p = 0.78)	−2.18 (−18.29%)	−2.47 (−20.95%)	−2.14 (−16.90%)
Mean micturition volume per voiding
Baseline	147.22 ± 51.11	154.03 ± 49.77	147.74 ± 49.06
Visit 3	171.09 ± 62.77	189.63 ± 63.24	167.86 ± 53.05
Visit 4	175.44 ± 62.21	194.56 ± 75.21	165.35 ± 58.61
Visit 5	181.11 ± 59.44	196.98 ± 69.96	177.93 ± 68.26
End-point	177.38 ± 59.08	198.99 ± 73.58	177.08 ± 66.41
End-point baseline (p = 0.53)	30.16 (25.89%)	44.97 (33.36%)	29.34 (26.69%)
Mean daily urgency incontinence frequency
Baseline	1.92 ± 2.19	2.58 ± 2.91	1.74 ± 1.55
Visit 3	0.97 ± 1.49	0.76 ± 1.10	0.90 ± 1.16
Visit 4	0.95 ± 1.81	0.77 ± 1.17	1.03 ± 1.41
Visit 5	0.78 ± 1.76	0.72 ± 1.51	0.67 ± 1.16
End-point	0.78 ± 1.74	0.75 ± 1.49	0.72 ± 1.18
End-point baseline (p = 0.14)	−1.14 (−59.38%)	−1.84 (−57.60%)	−1.02 (−52.30%)
Mean daily number of urgency episodes
Baseline	4.29 ± 3.45	3.81 ± 3.04	3.89 ± 3.12
Visit 3	2.32 ± 3.00	2.09 ± 2.49	2.32 ± 2.86
Visit 4	2.11 ± 2.74	1.72 ± 2.40	1.83 ± 2.54
Visit 5	1.77 ± 2.74	1.42 ± 2.21	1.60 ± 2.88
End-point	1.79 ± 2.66	1.47 ± 2.34	1.68 ± 3.02
End-point baseline (p = 0.51)	−2.50 (−57.72%)	−2.35 (−63.50%)	−2.20 (−55.43%)
Mean number of nocturia episodes
Baseline	1.82 ± 1.27	1.73 ± 1.07	1.77 ± 1.00
Visit 3	1.34 ± 1.14	1.28 ± 0.99	1.40 ± 0.96
Visit 4	1.31 ± 1.19	1.11 ± 0.98	1.25 ± 1.02
Visit 5	1.13 ± 1.12	1.07 ± 0.94	1.17 ± 1.09
End-point	1.15 ± 1.11	1.14 ± 1.01	1.23 ± 1.13
End point baseline (p = 0.85)	−0.67 (−31.41%)	−0.60 (−28.88%)	−0.54 (−24.85%)